Quarterly Result10 Feb 2026, 12:23 pm
Anlon Healthcare Limited Reports 20x EBITDA Growth and Strongly Positive PAT in Q3 FY26; Completes Strategic Acquisitions
AI Summary
Anlon Healthcare Limited, a leading manufacturer of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), announced its unaudited financial results for Q3 and 9M FY26. The company reported strong growth in revenue, profitability, and margins, driven by robust R&D execution and strategic capacity expansion initiatives. Anlon also completed strategic acquisitions, expanding its consolidated manufacturing capacity and strengthening its operational and regulatory capabilities.
Key Highlights
- Anlon Healthcare Limited reports 20x EBITDA growth and strongly positive PAT in Q3 FY26
- Company records Total Income of INR 35.78 crore in Q3 FY26, representing a YoY growth of 281.5%
- EBITDA at INR 12.54 crore and Profit After Tax of INR 5.15 crore in Q3 FY26
- Acquired 67.48% equity stake in Apiqo Organics Private Limited for INR 5.40 crore
- Acquisition of Bizotic Lifescience pending, expected to become a subsidiary upon completion